Article | July 6, 2018

The Transparent CDMO: Maintaining Autonomy In Your Biomanufacturing Partnership

Source: GE Healthcare Life Sciences

By Patrick Guertin

The Transparent CDMO

The complexities of today’s biologics and intensifying competition in the industry are making it more important than ever to develop a successful first-to-market strategy. Collaboration with a contract development and manufacturing organization (CDMO) can make it possible to bring your drug to  market — and to patients — faster, as additional resources allow your operations to run more smoothly, and you can react faster when problems arise. Nonetheless, handing over vital information about your product can understandably feel like you are giving up, or even losing power over, your own project.

That is why it is important to find a partner who can help alleviate the risks associated with drug development but also understands how to work in a fashion that protects your intellectual property (IP). Complete transparency and open communication are key factors in doing so. But how do you know your CDMO is prepared to offer that type of commitment to your project, and what business practices should you look for to ensure they can?